Clinical Trials Browser

Phase 2 × Recruiting × Adenoma, Islet Cell × Clear all

NCT04924075 2026-05-11

MK-6482-015

Phase 2 Recruiting

322 enrolled 1 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT06202066 2026-03-11

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Phase 2 Recruiting

Adenoma, Islet Cell

NCT05040360 2025-12-15

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Phase 2 Recruiting

Adenoma, Islet Cell

NCT05997056 2024-07-16

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Phase 2 Recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06472388 2024-06-25

EVENET

Phase 2 Recruiting

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression